Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads

Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting.

The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported pathologists in re-assessing and updating the initial diagnosis or Grade Group for 5% of patients. Notably, 1.3% of these changes were significant enough to potentially alter the patient's clinical management.

The study, led by Professor Clare Verrill at the University of Oxford’s Nuffield Department of Surgical Sciences, examined how using the Paige Prostate Suite impacted pathologists’ clinical decision-making, pathology service delivery and use of resources across three prominent UK National Health Service (NHS) trusts: Oxford University Hospitals NHS Foundation Trust, North Bristol NHS Trust and University Hospitals Coventry and Warwickshire NHS Trust. Biopsies from more than 1,000 patients were assessed in real time by expert histopathologists assisted by the AI suite.

Key impacts on clinical decision-making and laboratory efficiency included:

Enhanced Diagnostic Precision: The AI technology deployed within NHS IT infrastructure successfully flagged subtle, difficult-to-spot cancerous lesions and prompted pathologists to make appropriate changes to tumor aggressiveness grading. In several cases, this helped optimize the clinical management options offered to patients.
Accelerated Turnaround Times: Laboratories using the technology reported quicker diagnostic turnaround times, meaning patients could potentially receive their results nearly a day sooner than standard workflows allow.
Optimized Resource Allocation: The integration of the Paige Prostate Suite demonstrated a notable reduction in requests for extra immunohistochemistry (IHC) staining. This efficiency could provide overstretched digital pathology labs with workflow relief and cost savings.

"The rigorous, real-world results in the Articulate Pro study are a massive step forward for the global adoption of digital pathology," said Razik Yousfi, Senior Vice President and General Manager of AI Products at Tempus. "Integration of the Paige Prostate Suite directly into routine workflows shows that AI doesn't just work in a sandbox; it can actively alleviate the immense pressure on overstretched laboratories, cut down reporting times and give pathologists an extra layer of confidence when making critical diagnostic decisions."

The Paige Prostate Suite is a group of AI-powered applications designed to aid in the detection and grading of prostate cancer. Certain of the applications included within the Paige Prostate Suite are FDA-authorized and/or CE-marked and UKCA-marked for clinical use with certain slide image viewers and scanners, while others are currently offered only for research use.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716546846/en/

Tempus Communications

Hanah Heintzelman

hanah.heintzelman@tempus.com